CME Obesity Risk Factors 
Cardiometabolic Health Congress
AUGUST 14, 2024
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. Chair: Erin D. Presenter: Pamela B.
Cardiometabolic Health Congress
JULY 25, 2024
Here’s what you can expect at the biggest conference in cardiorenal metabolic health, the 19th Annual Cardiometabolic Congress (CMHC), DECODING THE CONSTELLATION of Cardiometabolic Health and Risk Factors. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
Cardiometabolic Health Congress
JULY 12, 2023
A vast collection of webinars, CME activities, expert interviews, on-demand event recordings, news articles, drug pipelines, and many other resources are now grouped into areas of specialty focus. For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity.
Cardiometabolic Health Congress
FEBRUARY 23, 2024
Black History Month is a poignant backdrop to the alarming rise in obesity and type 2 diabetes, particularly among those of marginalized populations. Two major risk factors for CVD are hypertension and diabetes, which also place a heavier burden on minority groups.
Cardiometabolic Health Congress
NOVEMBER 14, 2024
cardiometabolic health CME/CE conference: the 19th Annual CMHC. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors.
Cardiometabolic Health Congress
NOVEMBER 8, 2024
Healthcare professionals should consider pharmacotherapy options that address T2D, obesity, and liver disease: Statins : Statins are first-line therapies for managing dyslipidemia and reducing cardiovascular risk in patients with MASH. It significantly reduces liver fat content and improves glycemic control and insulin sensitivity.
Expert insights. Personalized for you.
72 
Let's personalize your content